• <xmp id="kkgi4">
    <td id="kkgi4"><kbd id="kkgi4"></kbd></td>
  • <td id="kkgi4"></td>
  • <table id="kkgi4"><noscript id="kkgi4"></noscript></table>
  • 愛硒健康網丨癌癥腫瘤治療助手

    兩大乳腺癌ADC頭對頭研究結果出爐;K藥宮頸癌布局即將上線|ESMO LBA

    編者按:
    • 神仙打架!兩大乳腺癌ADC藥物頭對頭試驗結果出爐——LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY Breast 03 study.


    • 不“看”PD-L1表達狀態,K藥聯合化療治療復發轉移性性宮頸癌PFS、OS雙贏——LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study.


    • 高危Ⅱ期黑色素瘤輔助治療,K藥戰線再進一步——LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial.


    以上精彩盡在:



    – End –

    加硒教授微信:623296388,送食療電子書,任選一本

    分享到:更多 ()

    評論 搶沙發

    • 昵稱 (必填)
    • 郵箱 (必填)
    • 網址
  • <xmp id="kkgi4">
    <td id="kkgi4"><kbd id="kkgi4"></kbd></td>
  • <td id="kkgi4"></td>
  • <table id="kkgi4"><noscript id="kkgi4"></noscript></table>
  • 国产又粗又猛又爽又黄的视频